# Millions of People Have Used Psilocybin in the Past Year | Cannabis Equipment News > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/millions-of-people-have-used-psilocybin-in-the-past-year-cannabis-equipment-news/ > **Published:** 2026-06-10T10:37:14-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T10:52:53-04:00 > **Clinical Summary:** 2024 NSDUH data on psilocybin use prevalence. Clinical guidance on screening and patient counseling for psychedelic exposure. --- ✦ New CED Clinical Relevance #75 Strong Clinical Relevance High-quality evidence with meaningful patient or clinical significance. Research[Mental Health](https://cedclinic.com/cannabis-psychiatric-research-findings-depression-anxiety/)PolicySafetyNeurologyAnxietyAging Clinical Summary # Clinical Summary The 2024 National Survey on Drug Use and Health, conducted among 58,000 U.S. respondents age 12 and older, reveals substantial past-year psilocybin use across the American population, indicating a significant shift in psychedelic substance exposure and potential [public health](https://cedclinic.com/cannabis-mold-contamination-risks-recall-safety/) implications. While this survey data does not directly measure therapeutic use, the prevalence findings underscore growing recreational and self-directed access to psilocybin outside clinical settings, occurring amid emerging [clinical trials](https://cedclinic.com/endocannabinoid-system-emotional-memory-ptsd-treatment/) demonstrating efficacy for treatment-resistant depression and other psychiatric conditions. Clinicians should recognize that patients presenting with mood or [anxiety disorders](https://cedclinic.com/adolescent-cannabis-use-and-anxiety-research/) may have undisclosed psilocybin exposure history, which carries relevance for [drug interactions](https://cedclinic.com/cannabis-liver-interactions-study-insights/), psychiatric evaluation, and understanding patients’ motivation to seek psychedelic-assisted therapy. The gap between widespread population use and the limited availability of regulated, clinical psilocybin treatment creates a situation where patients may pursue uncontrolled sources rather than evidence-based protocols. Clinicians should proactively inquire about psilocybin use during substance history screening and stay informed about evolving clinical trial data and potential future regulatory pathways for psychedelic-assisted therapy to better counsel patients on risks and emerging legitimate options. Dr. Caplan’s Take “We’re seeing a fundamental shift in how Americans perceive psychedelics, much like we witnessed with cannabis over the past decade, and that cultural change is outpacing our clinical evidence base, which means responsible physicians need to stay ahead of patient curiosity rather than behind it.” Clinical Perspective 💊 The 2024 National Survey on Drug Use and Health’s finding that millions of Americans have used psilocybin in the past year reflects growing accessibility and shifting cultural perceptions, though interpreting this prevalence figure requires careful consideration of confounding factors including survey respondent bias, recall accuracy, and the distinction between one-time experimentation and regular use. While psilocybin has shown promising therapeutic potential in [clinical trials](https://cedclinic.com/endocannabinoid-system-emotional-memory-ptsd-treatment/) for treatment-resistant depression and end-of-life anxiety, the epidemiological landscape of non-clinical use differs substantially from controlled research settings, and we lack reliable data on how many users are self-medicating versus recreationally experimenting. Clinicians should recognize that increasing prevalence of psilocybin use in their patient populations means screening for psychedelic use should become routine, particularly for patients with psychiatric histories, given the potential for adverse interactions with medications and underlying vulnerabilities to psychotic disorders. The gap 💬 Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/forum/cannabis-related-research/) Have thoughts on this? Share it: [X Share on X](https://twitter.com/intent/tweet?text=Just%20read%20this%20on%20CEDclinic.com%3A%20Millions%20of%20People%20Have%20Used%20Psilocybin%20in%20the%20Past%20Year%20%7C%20Cannabis%20Equipment%20News%20%40drcaplan&url=https%3A%2F%2Fcedclinic.com%2F%3Fp%3D58720)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fcedclinic.com%2F%3Fp%3D58720)[🦅 Share on BlueSky](https://bsky.app/intent/compose?text=Just%20read%20this%3A%20Millions%20of%20People%20Have%20Used%20Psilocybin%20in%20the%20Past%20Year%20%7C%20Cannabis%20Equipment%20News%20via%20%40drcaplan.bsky.social%20https%3A%2F%2Fcedclinic.com%2F%3Fp%3D58720)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan)[📝 Read more on Substack](https://doctorapprovedcannabis.substack.com/)[🔔 Subscribe via RSS](https://cedclinic.com/feed/) Related Articles - [CED Digest: 436 Items — March 14, 2026](https://cedclinic.com/cannabis-compounds-fatty-liver-disease-2026/) - [CED Digest: 405 Items — March 12, 2026](https://cedclinic.com/alabama-medical-cannabis-sales-2026-spring-launch/) 📰 Source: [https://www.cannabisequipmentnews.com/news/news/22968566/millions-of-people-have-used-psilocybin-in-the-past-year](https://www.cannabisequipmentnews.com/news/news/22968566/millions-of-people-have-used-psilocybin-in-the-past-year) Further Reading CED Clinic Blog[Why Cannabis Works](https://cedclinic.com/why-cannabis-works/) Evidence Watch[Cannabis and Heart Health](https://cedclinic.com/cannabis-cardiovascular-health-study/) CED Clinic Blog[Cannabis for Sleep](https://cedclinic.com/cannabis-for-sleep/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Former CMO Canna Care Docs (250,000+ patients supervised), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).